Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) is one of the most extensively studied and utilized viral vectors in clinical gene transfer research. However, the serum instability and immunogenicity of AAV vectors significantly limit their application. Here, we endeavored to overcome these limitations by developing a straightforward approach for site-specific PEGylation of AAV via genetic code expansion. This technique includes incorporation of the azide moiety into the AAV capsid protein followed by orthogonal and stoichiometric conjugation of a variety of polyethylene glycols (PEGs) through click chemistry. Using this approach, only the chosen site(s) was consistently PEGylated under mild conditions, preventing nonselective conjugation. Upon a series of in vitro examinations, AAVs conjugated with 20-kD PEG at sites Q325+1, S452+1, and R585+1 showed a 1.7- to 2.4-fold stability improvement in pooled human serum and a nearly twofold reduction in antibody recognition. Subsequent animal research on Sprague Dawley rats displayed a promising 20% reduction in antibody inducement and a higher virus titer in the blood. Together, our data demonstrate successful protection of an AAV vector from antibody neutralization and blood clearance, thereby increasing the efficiency of therapeutic gene delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, another study using the PEGylation at UAA site strategy encountered the issue of decreased titer as well, although antibody recognition was modestly improved (140).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 1×
“PEGylation is a well-established technique for improving the pharmacokinetics and pharmacodynamics of protein pharmaceuticals [25] and has been widely investigated in viral vector protection, including in adenovirus production [26,27].”
MethodExpanding the Genetic Code of Escherichia coli
Wang, L., Brock, A., Herberich, B., & Schultz, P. G. (2001) · Science · doi:10.1126/science.1060077 · Cited by 1,499 · cited 1×
“In this study, we used a straightforward and precise strategy of genetic code expansion [30,31] for PEGylation of recombinant AAV-2 vectors.”
MethodBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“Given that most people have already been exposed to AAV and consequently have antibodies against AAV [13,14,16], the clinical application of AAV vectors is greatly restricted.”
BackgroundAn Expanded Eukaryotic Genetic Code
Chin, J. W., Cropp, T. A., Anderson, J. C., Mukherji, M., Zhang, Z., & Schultz, P. G. (2003) · Science · doi:10.1126/science.1084772 · Cited by 820
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 3×
“Given that most people have already been exposed to AAV and consequently have antibodies against AAV [13,14,16], the clinical application of AAV vectors is greatly restricted.”
BackgroundMethodThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 1×
“This determination was based on previous studies of AAV capsid protein modification and the crystal structure of AAV [35], taking the steric hindrance of NAEK insertion into consideration.”
MethodWu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., & Muzyczka, N. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8635-8647.2000 · Cited by 390 · cited 1×
“These sites were chosen after considering their tolerance, location, and potential functions, which were selected to avoid involvement in host cell recognition, receptor binding, or host–virus membrane fusion [33].”
BackgroundPre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358 · cited 1×
“Moreover, even quite low levels of antibodies can prevent successful transduction [17].”
BackgroundOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
Site-specific PEGylation of proteins containing unnatural amino acids
Deiters, A., Cropp, T. A., Summerer, D., Mukherji, M., & Schultz, P. G. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.09.059 · Cited by 262 · cited 1×
“In this study, we used a straightforward and precise strategy of genetic code expansion [30,31] for PEGylation of recombinant AAV-2 vectors.”
MethodMoskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253
Adeno-associated virus (AAV) vectors in cancer gene therapy
Santiago-Ortiz, J. L., & Schaffer, D. V. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.001 · Cited by 228 · cited 1×
“Utilized as a tool for gene therapy, recombinant AAV (rAAV) vectors have been constructed by removing endogenous viral genes and inserting expression cassette(s) between the flanking ITRs, thus carrying exogenous genes into target cells [12].”
MethodTse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210
Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice
Mearini, G., Stimpel, D., Geertz, B., Weinberger, F., Krämer, E., Schlossarek, S., Mourot-Filiatre, J., Stoehr, A., Dutsch, A., Wijnker, P. J. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6515 · Cited by 172
PEG conjugation moderately protects adeno‐associated viral vectors against antibody neutralization
Lee, G. K., Maheshri, N., Kaspar, B., & Schaffer, D. V. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20562 · Cited by 169 · cited 3×
“Since it has been reported that PEG coverage may compromise the transduction efficiency of virus vectors in vivo [28], a pilot study was first initiated to evaluate the effect of PEGylation using our site-specific modification method.”
BackgroundMethodInfluentialQu, G., Bahr-Davidson, J., Prado, J., Tai, A., Cataniag, F., McDonnell, J., Zhou, J.-M., Hauck, B., Luna, J., Sommer, J. M., et al. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.11.019 · Cited by 163 · cited 1×
“The isolation and purification of rAAV2 from the cell lysis fraction by anion-exchange column chromatography was performed with AKTA pure as previously reported [36].”
MethodPrecise hit: adeno-associated virus in gene targeting
Vasileva, A., & Jessberger, R. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1266 · Cited by 157 · cited 1×
“As a significant component of viral vectors used in gene therapy, AAV has many advantages, including its nonpathogenic nature [2,3], long-term stable gene expression [4–8], and the ability to infect both dividing and non-dividing cells [9–11].”
BackgroundRohr, U., Wulf, M.-A., Stahn, S., Steidl, U. G., Haas, R. R., & Kronenwett, R. (2002) · Journal of Virological Methods · doi:10.1016/s0166-0934(02)00138-6 · Cited by 146 · cited 1×
“The preparation of samples, the construction of a standard curve, and the PCR process were performed under the guidance of a previous study [37].”
MethodSehara, Y., Fujimoto, K.-I., Ikeguchi, K., Katakai, Y., Ono, F., Takino, N., Ito, M., Ozawa, K., & Muramatsu, S.-I. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.010 · Cited by 141
Choudhury, S. R., Harris, A. F., Cabral, D. J., Keeler, A. M., Sapp, E., Ferreira, J. S., Gray-Edwards, H. L., Johnson, J. A., Johnson, A. K., Su, Q., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.231 · Cited by 113
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94 · cited 1×
“, AAV-specific CD8+ T cells) that are also induced by natural infections [18].”
BackgroundBortolussi, G., Zentillin, L., Jašprová, J., Bočkor, L., Bellarosa, C., Mancarella, A., Vianello, E., Tiribelli, C., Giacca, M., Vítek, L., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.233 · Cited by 88
Utility of PEGylated recombinant adeno-associated viruses for gene transfer
Le, H. T., Yu, Q.-C., Wilson, J. M., & Croyle, M. A. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.019 · Cited by 82 · cited 1×
“modified rAAV-2 capsids with PEGs activated by cyanuric chloride (CCPEG), succinimidyl succinate (SSPEG), and tresyl chloride (TMPEG) and demonstrated that AAV conjugated with SSPEG was susceptible to neutralizing antibodies, whereas TMPEG afforded the best protection from neutralization both in vitro and in vivo with…”
MethodHighly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina
Boye, S. L., Alexander, J. J., Witherspoon, C. D., Boye, S. L., Peterson, J. J., Clark, M. E., Sandefer, K. J., Girkin, C. A., Hauswirth, W. W., & Gamlin, P. D. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.085 · Cited by 82
Mimuro, J., Mizukami, H., Hishikawa, S., Ikemoto, T., Ishiwata, A., Sakata, A., Ohmori, T., Madoiwa, S., Ono, F., Ozawa, K., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.258 · Cited by 79
Thwaite, R., Pagès, G., Chillón, M., & Bosch, A. (2015) · Gene Therapy · doi:10.1038/gt.2014.103 · Cited by 76 · cited 1×
“To alleviate the neutralization effect of antibodies against AAV vectors, especially those that target capsid proteins, several approaches have been used, including the use of alternative serotype vectors (AAV1–10) [16,19], different routes of administration [20], immune suppression [21], capsid engineering, encapsula…”
MethodZhang, C., Yao, T., Zheng, Y., Li, Z., Zhang, Q., Zhang, L., & Zhou, D. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.066 · Cited by 61 · cited 3×
“The production method for site-specific mutated rAAV-2 was based on a previous study from our lab [34].”
BackgroundMethodResultSelf-citationPEGylated Adenoviruses: From Mice to Monkeys
Wonganan, P., & Croyle, M. A. (2010) · Viruses · doi:10.3390/v2020468 · Cited by 60 · cited 1×
“PEGylation is a well-established technique for improving the pharmacokinetics and pharmacodynamics of protein pharmaceuticals [25] and has been widely investigated in viral vector protection, including in adenovirus production [26,27].”
MethodSpecies Differences in the Pharmacology and Toxicology of PEGylated Helper-Dependent Adenovirus
Wonganan, P., Clemens, C. C., Brasky, K., Pastore, L., & Croyle, M. A. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100216h · Cited by 38 · cited 1×
“PEGylation is a well-established technique for improving the pharmacokinetics and pharmacodynamics of protein pharmaceuticals [25] and has been widely investigated in viral vector protection, including in adenovirus production [26,27].”
MethodLing, C., Wang, Y., Feng, Y., Zhang, Y., Li, J., Hu, X.-R., Wang, L., Zhong, M., Zhai, X., Zolotukhin, I., et al. (2015) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(15)60200-x · Cited by 37
Tarantal, A. F., Lee, C. C. I., Martinez, M. L., Asokan, A., & Samulski, R. J. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.130 · Cited by 32
Hardet, R., Chevalier, B., Dupaty, L., Naïmi, Y., Riou, G., Drouot, L., Jean, L., Salvetti, A., Boyer, O., & Adriouch, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.146 · Cited by 26
Extracellular Vesicles as Enhancers of Virus Vector–Mediated Gene Delivery
Fitzpatrick, Z., György, B., Skog, J., & Maguire, C. A. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.082 · Cited by 17
Vidović, D., Gijsbers, R., Quiles‐Jiménez, A., Dooley, J., den Haute, C. V., der Perren, A. V., Liston, A., Baekelandt, V., Debyser, Z., & Carlon, M. S. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.109 · Cited by 12
Vil, L., Roca, C., Elias, I., Casellas, A., Lage, R., Franckhauser, S., & Bosch, F. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.72 · Cited by 11
Research works printed but not linked: 2
- Fields, B., Knipe, D., Howley, P., and Griffin, D. (2007). Fields Virology, Lippincott Williams & Wilkins. [5th ed.].
- Muzyczka, 2001, Parvoviridae: The viruses and their replication, Fields Virol., 2, 2327
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“A study used PEG-N-hydroxysuccinimide with an electro-philic succinimidyl propionic acid functional group to cross-link with lysine residues on rAAV2 capsid to enable NAb evasion.”
BackgroundAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans
Shen, Y., Campbell, R. E., Côté, D. C., & Paquet, M.-È. (2020) · Frontiers in Neural Circuits · doi:10.3389/fncir.2020.00041 · Cited by 120
“Alternatively, as regions of the AAV capsid important for antibody binding have been identified, inserting mutations in these residues could abolish epitope recognition (Kotterman and Schaffer, 2014), or the AAV could be pegylated to shield the virus capsid from the immune system (Yao et al., 2017).”
Background
Metadata
- Authors
- Yao, T., Zhou, X., Zhang, C., Yu, X., Tian, Z., Zhang, L., & Zhou, D.
- Affiliations
- Peking University (CN)
- Corresponding author
- Zhang, Chuanling
- Zhou, Demin
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2017-07-11
- Volume
- 22
- Issue
- 7
- Pages
- 1155
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6152081
- OpenAlex
- W2735631314
- Cited by
- 68
- References
- 35
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 11 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 5
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81530090, 81673342, 81361168002, 2016YFA0501500)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- adeno-associated virus, site-specific PEGylation, genetic code expansion, click chemistry, serum stability, immunogenicity, antibody neutralization, gene therapy vectors, blood clearance
- MeSH terms
- Dependovirus, Animals, Antibody Formation, Binding Sites, Cell Line, Genetic Vectors, Humans, Immunity, Active, Male, Mutation, Polyethylene Glycols, Surface Properties, Rats, Sprague-Dawley, Gene Transfer Techniques, Capsid Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.